Healthcare Pulse: Sanofi SA (ADR) (SNY), GlaxoSmithKline plc (ADR) (GSK), and Boston Scientific Corporation (BSX)

Marketing teams at Sanofi SA (ADR) (NYSE:SNY) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) are ramping up efforts ahead of lead cholesterol drug Alirocumab, making its debut next year. Analysts expect the drug to generate billions of dollars in sales. Recent trial data has already shown how the drug can be relied upon by patients.

A marketing campaign by the two companies strives to get patients serious about getting their cholesterol levels under control. Sanofi SA (ADR) (NYSE:SNY)’s new drug has already received a boost in the market in comparison with Zetia. Statistics show that Alirocumab beat Zetia in a head to head trial, showing a 45% reduction in LDL levels in patients who can’t tolerate statins

Sanofi SA (ADR) (NYSE:SNY) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) new drug is already proving to be more potent and more effective lipid-lowering drug. The two haven’t yet sought FDA approval but by using a priority review voucher they could have it on the market as early as next year.

GlaxoSmithKline plc (ADR) (NYSE:GSK) new sales model has been cited as a possible reason for sluggish sales for blockbuster hopefuls Breo and Anoro. The two respiratory outcomes were highly expected to offset plummeting sales of Advair another drug that continues to struggle amidst pricing pressure from generics.

The new drugs generated £10 million in sales in Q2 way below analysts’ estimates as concerns continue to grow that the trend could persist

A change of compensation practices has reportedly affected sales reps morale in the sale of the company’s drugs. The new system pays more attention to reps emphasizing the quality of the drugs as well as information exchange, rather than paying attention on individual sales quotas.

Critics argue that individual quotas lack the much-needed motivation to push GlaxoSmithKline plc (ADR) (NYSE:GSK) drugs in the highly crowded respiratory landscape. The drug maker is, however, remaining firm reiterating that the new model could provide a competitive advantage going forward.

Boston Scientific Corporation (NYSE:BSX) has received the first FDA approval and CE Mark for AngioJet catheter, for treating deep veins thrombosis. The company’s AngioJet ZelanteDVT can now be used to address the needs of the more than 2.5 million people in Europe and US, affected by the condition

Deep veins thrombosis occurs whenever a blood clot forms in one or more of the deep veins mostly in legs. Left untreated, the condition can lead to life-threatening complications. AngioJet ZelanteDVT should offer four times thrombus removal power compared to the current products on the market.

Boston Scientific Corporation (NYSE:BSX) says the drug was developed to efficiently remove large venous clot burdens. That way, it should be able to facilitate rapid restoration of blood flow thereby decreasing procedural time and alleviating chances of late complications.

Viraj Shah

Viraj Shah has completed M.Com (Finance) and is currently pursuing his CFP. He tracks US markets along with other global markets like India very closely. He is very passionate about stocks, real estate, and technology. He also believes that money can always be made in the market.

You may also like...

escort kutahya escort bornova escort beylikduzu escort amasya escort diyarbakir
More in BSX, GSK
GlaxoSmithKline plc (ADR) (NYSE:GSK)
Weekly Recap 11-16/11-20: GlaxoSmithKline plc (ADR) (GSK), Valeant Pharmaceuticals Intl Inc (VRX), and Microsoft Corporation (MSFT)

GlaxoSmithKline plc (ADR) (NYSE:GSK) is quietly engaged in the process of revolutionizing medicine globally. For this, the company has involved...